HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 65.9%

Neg 0% Neu 65.9% Pos 0%

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.